Shyam Bhakta, MD Division of Cardiology, Case Western Reserve University/University Hospitals of Cleveland
Mark E. Dunlap, MD Director, Heart Failure Program and Associate Chief, Cardiology Section, Louis B. Stokes Veterans Affairs Medical Center; Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University, Cleveland; national leader, Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial
Address: Mark E. Dunlap, MD, Cardiology Section, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, OH 44106
Dr. Dunlap has indicated that he has received grant or research support from, is a consult for, and is on the speakers’ bureau of the AstraZeneca corporation, the maker of candesartan.
This paper discusses therapy that is experimental or not approved by the US Food and Drug Administration for the use under discussion.
ABSTRACTThe large Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial recently found that in patients with heart failure who were similar to those whom clinicians see in everyday practice, the angiotensin-receptor blocker candesartan was not only an acceptable alternative to angiotensin-converting enzyme (ACE) inhibitors, but also was beneficial when added to regimens that already included ACE inhibitors and beta-blockers. Candesartan was beneficial in heart failure patients with or without left ventricular systolic dysfunction.
